Matrix Capital Management Company’s Avidity Biosciences RNAM Stock Holding History

Matrix Capital Management Company’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,200,000	Closed	-$29.7M	–	25
2021 Q2	$29.7M	Hold	1,200,000	–	–	0.32%	23
2021 Q1	$26.2M	Hold	1,200,000	–	–	0.3%	28
2020 Q4	$30.6M	Hold	1,200,000	–	–	0.33%	28
2020 Q3	$33.8M	Hold	1,200,000	–	–	0.45%	25
2020 Q2	$33.9M	Buy	+1,200,000	New	+$34.6M	0.53%	23

Other funds holding RNAM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Matrix Capital Management Company's RNAM Position: Q3 2021 in Review

Matrix Capital Management Company sold out of Avidity Biosciences (RNAM) in Q3 2021, closing a stake of 1,200,000 shares — an estimated $29.7M sold.

Matrix Capital Management Company first reported a position in RNAM in Q2 2020 and held it in 5 quarters. The position peaked at $33.9M in Q2 2020. 111 funds tracked by Wall St. Rank hold RNAM as of Q3 2021.

Matrix Capital Management Company reported no remaining Avidity Biosciences position as of Q3 2021 after selling out during the quarter.
Matrix Capital Management Company sold 1,200,000 Avidity Biosciences shares in Q3 2021, an estimated $29.7M.
Matrix Capital Management Company first reported a position in Avidity Biosciences in Q2 2020 and held it in 5 quarters.
Matrix Capital Management Company's Avidity Biosciences position peaked at $33.9M in Q2 2020.
111 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2021.

Based on Matrix Capital Management Company's 13F filing for Q3 2021, filed 15 Nov 2021.